Mesoblast Ltd
ASX:MSB

Watchlist Manager
Mesoblast Ltd Logo
Mesoblast Ltd
ASX:MSB
Watchlist
Price: 1.72 AUD -3.91% Market Closed
Market Cap: 2.2B AUD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one MSB stock under the Base Case scenario is 2.1 AUD. Compared to the current market price of 1.72 AUD, Mesoblast Ltd is Undervalued by 18%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MSB Relative Value
Base Case
2.1 AUD
Undervaluation 18%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

252.3
P/S
P/S
Price to Sales
252.3
vs History
14
vs Industry
9
Median 3Y
92.2
Median 5Y
122.8
Industry
7.2
Forward
87.1
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-9.1
Median 5Y
-12.5
Industry
23.2
Forward
-27.9
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-13.5
Median 5Y
-15.9
Industry
19.3
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-13
Median 5Y
-14.5
Industry
22.5
More Details
3.1
P/B
P/B
Price to Book Value
3.1
vs History
28
vs Industry
27
Median 3Y
1.7
Median 5Y
2
Industry
2.7
More Details
264.3
EV/S
EV/S
Enterprise Value to Sales
264.3
vs History
14
vs Industry
6
Median 3Y
96.7
Median 5Y
126.4
Industry
7.5
Forward
91.3
More Details
131
EV/GP
EV/GP
Enterprise Value to Gross Profit
131
vs History
15
vs Industry
7
Median 3Y
-32.2
Median 5Y
-44.9
Industry
9.4
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-12.1
Median 5Y
-14.5
Industry
4.6
Forward
-24.6
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-12.1
Median 5Y
-14.5
Industry
4.5
Forward
-22.5
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-14.4
Median 5Y
-15.7
Industry
4.9
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-14.3
Median 5Y
-15.5
Industry
3.7
More Details
2.5
EV/IC
EV/IC
Enterprise Value to IC
2.5
vs History
34
vs Industry
41
Median 3Y
1.5
Median 5Y
1.8
Industry
4.9
More Details

Multiples Across Competitors

MSB Competitors Multiples
Mesoblast Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Mesoblast Ltd
ASX:MSB
2.2B AUD 252.3 -13.8 -18.7 -18.7
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 559 828.3 -164 257.7 -199 461.3 -197 185.2
US
Abbvie Inc
NYSE:ABBV
327.6B USD 5.7 78.9 15.1 22.3
US
Amgen Inc
NASDAQ:AMGN
155.7B USD 4.6 26.2 14.2 23.3
US
Gilead Sciences Inc
NASDAQ:GILD
134.5B USD 4.7 22.5 9.8 13.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.2B USD 10.4 -116.5 24.7 25.9
US
Epizyme Inc
F:EPE
94.1B EUR 2 038.5 -520.2 -566.4 -551.3
AU
CSL Ltd
ASX:CSL
115.8B AUD 4.9 27.4 16.9 21.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
55.6B USD 3.9 12.4 11 12.3
US
Seagen Inc
F:SGT
39.3B EUR 19.6 -60.2 -64.9 -58.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
40.7B USD 17.3 -150.9 -676.2 -338.8
P/S Multiple
Revenue Growth P/S to Growth
AU
Mesoblast Ltd
ASX:MSB
Average P/S: 3 142 017.3
252.3
245%
1
FR
Pharnext SCA
OTC:PNEXF
34 559 828.3
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.7
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.6
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.7
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.4
10%
1
US
E
Epizyme Inc
F:EPE
2 038.5
N/A N/A
AU
CSL Ltd
ASX:CSL
4.9
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
3.9
4%
1
US
S
Seagen Inc
F:SGT
19.6
30%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
17.3
29%
0.6
P/E Multiple
Earnings Growth PEG
AU
Mesoblast Ltd
ASX:MSB
Average P/E: 33.5
Negative Multiple: -13.8 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -164 257.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
78.9
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
26.2
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
22.5
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -116.5 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -520.2 N/A N/A
AU
CSL Ltd
ASX:CSL
27.4
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.4
7%
1.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.2 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -150.9 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Mesoblast Ltd
ASX:MSB
Average EV/EBITDA: 15.3
Negative Multiple: -18.7 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -199 461.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.1
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.2
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
9.8
6%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.7
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -566.4 N/A N/A
AU
CSL Ltd
ASX:CSL
16.9
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11
11%
1
US
S
Seagen Inc
F:SGT
Negative Multiple: -64.9 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -676.2 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Mesoblast Ltd
ASX:MSB
Average EV/EBIT: 19.8
Negative Multiple: -18.7 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -197 185.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.3
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.3
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.6
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.9
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -551.3 N/A N/A
AU
CSL Ltd
ASX:CSL
21.2
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.3
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.5 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -338.8 N/A N/A

See Also

Summary
MSB intrinsic value, competitors valuation, and company profile.
DCF Valuation
MSB stock valuation using Discount Cash Flow valuation method.
Relative Valuation
MSB stock valuation using valuation multiples.
Wall Street Estimates
MSB price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
MSB stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 262,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.